Demethylation of EHMT1/GLP protein reprograms its transcriptional activity and promotes prostate cancer progression

Anna Besschetnova,Wanting Han,Mingyu Liu,Yanfei Gao,Muqing Li,Zifeng Wang,Maryam Labaf,Susan Patalano,Kavita Venkataramani,Rachel E. Muriph,Jill A. Macoska,Kellee R. Siegfried,Jason Evans,Steven P. Balk,Shuai Gao,Dong Han,Changmeng Cai,Rachel E Muriph,Kellee R Siegfried

DOI: https://doi.org/10.1158/2767-9764.crc-23-0208

2023-08-10

Cancer Research Communications

Abstract:Epigenetic reprogramming, mediated by genomic alterations and dysregulation of histone reader and writer proteins, plays a critical role in driving prostate cancer (PCa) progression and treatment resistance. However, the specific function and regulation of EHMT1 (also known as GLP) and EHMT2 (also known as G9A), well-known histone 3 lysine 9 methyltransferase, in PCa progression remain poorly understood. Through comprehensive investigations, we discovered that both EHMT1 and EHMT2 proteins have the ability to activate oncogenic transcription programs in PCa cells. Silencing EHMT1/2 or targeting their enzymatic activity with small molecule inhibitors can markedly decrease PCa cell proliferation and metastasis in vitro and in vivo. In-depth analysis of posttranslational modifications of EHMT1 protein revealed the presence of methylation at lysine 450 and 451 residues in multiple PCa models. Notably, we found that lysine 450 can be demethylated by LSD1. Strikingly, concurrent demethylation of both lysine residues resulted in a rapid and profound expansion of EHMT1's chromatin binding capacity, enabling EHMT1 to reprogram the transcription networks in PCa cells and activate oncogenic signaling pathways. Overall, our studies provide valuable molecular insights into the activity and function of EHMT proteins during PCa progression. Moreover, we propose that the dual-lysine demethylation of EHMT1 acts as a critical molecular switch, triggering the induction of oncogenic transcriptional reprogramming in PCa cells. These findings highlight the potential of targeting EHMT1/2 and their demethylation processes as promising therapeutic strategies for combating PCa progression and overcoming treatment resistance.